A pilot clinical trial for adoptive transfer of ex-vivo IL-10-anergized Tr1 cells of donor origin using DC-10 (or monocytes + IL-10; IL-10 DLI) has been completed in patients affected by hematological malignancies, who underwent T-cell-depleted haploidentical hematopoietic stem cell transplantation (ALT-TEN protocol) [78,79]. Here, IL10 is linked to hematologic disorder.